KING PHARMACEUTICALS RESEARCH AND DEVELO – Trademark Portfolio

Entity Type: 03

KING PHARMACEUTICALS RESEARCH AND DEVELO holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include SONATA and CYTOMEL. The owner is based in New York, NY.

66 Hudson Boulevard East

New York, NY 100012192

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CYTOMEL
CYTOMEL
Registered 1997
SONATA
SONATA
Registered 1997

Trademark Classifications

KING PHARMACEUTICALS RESEARCH AND DEVELO's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does KING PHARMACEUTICALS RESEARCH AND DEVELO have?

KING PHARMACEUTICALS RESEARCH AND DEVELO has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does KING PHARMACEUTICALS RESEARCH AND DEVELO file in?

KING PHARMACEUTICALS RESEARCH AND DEVELO files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are KING PHARMACEUTICALS RESEARCH AND DEVELO's most well-known trademarks?

KING PHARMACEUTICALS RESEARCH AND DEVELO's registered trademark portfolio includes well-known marks such as SONATA and CYTOMEL. These are among 2 currently registered trademarks in the portfolio.

What is KING PHARMACEUTICALS RESEARCH AND DEVELO's trademark registration success rate?

KING PHARMACEUTICALS RESEARCH AND DEVELO has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.